Promise of Serological Biomarkers for Liver Fibrosis in NASH

Time: 2:00 pm
day: Post Conference Seminar Day


• Illustrating the need for biologically plausible serum/plasma) biomarkers of liver fibrosis stage, fibrosis progression and fibrosis resolution
• Describing liver fibrosis marker exploration, development and validation based on extracellular matrix biology and advanced proteomics technologies
• Demonstrating examples of the predictive value of novel fibrosis markers being validated in defined cohorts of (NASH) patients undergoing (antifibrotic) treatment